{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T14:38:48Z","timestamp":1789137528294,"version":"build-2803163510"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Med"],"DOI":"10.1007\/s10238-022-00904-2","type":"journal-article","created":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T10:02:30Z","timestamp":1667296950000},"page":"1741-1749","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Efficacy of fibrates in the treatment of primary biliary cholangitis: a meta-analysis"],"prefix":"10.1007","volume":"23","author":[{"given":"Haifu","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuojun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yonghang","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinxia","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biyun","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,1]]},"reference":[{"issue":"23","key":"904_CR1","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1056\/NEJMoa1714519","volume":"378","author":"C Corpechot","year":"2018","unstructured":"Corpechot C, et al. A placebo-controlled trial of bezafibrate in primary biliary cholangitis. N Engl J Med. 2018;378(23):2171\u201381.","journal-title":"N Engl J Med"},{"issue":"2","key":"904_CR2","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/s41575-019-0226-7","volume":"17","author":"AF Gulamhusein","year":"2020","unstructured":"Gulamhusein AF, Hirschfield GM. Primary biliary cholangitis: pathogenesis and therapeutic opportunities. Nat Rev Gastroenterol Hepatol. 2020;17(2):93\u2013110.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"1","key":"904_CR3","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/s41395-018-0390-3","volume":"114","author":"ZM Younossi","year":"2019","unstructured":"Younossi ZM, et al. Diagnosis and management of primary biliary cholangitis. Am J Gastroenterol. 2019;114(1):48\u201363.","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"904_CR4","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1002\/hep.30145","volume":"69","author":"KD Lindor","year":"2019","unstructured":"Lindor KD, et al. Primary biliary cholangitis: 2018 practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2019;69(1):394\u2013419.","journal-title":"Hepatology"},{"key":"904_CR5","doi-asserted-by":"crossref","unstructured":"European Association for the Study of the Liver. Electronic address, EEE and European Association for the Study of the L. EASL clinical practice guidelines: the diagnosis and management of patients with primary biliary cholangitis. J Hepatol 2017;67(1):145\u2013172.","DOI":"10.1016\/j.jhep.2017.03.022"},{"issue":"12","key":"904_CR6","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1016\/j.dld.2021.04.028","volume":"53","author":"A Floreani","year":"2021","unstructured":"Floreani A, De Martin S. Treatment of primary sclerosing cholangitis. Dig Liver Dis. 2021;53(12):1531\u20138.","journal-title":"Dig Liver Dis"},{"issue":"6","key":"904_CR7","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1016\/j.jhep.2021.01.013","volume":"74","author":"JM Schattenberg","year":"2021","unstructured":"Schattenberg JM, et al. A randomized placebo-controlled trial of elafibranor in patients with primary biliary cholangitis and incomplete response to UDCA. J Hepatol. 2021;74(6):1344\u201354.","journal-title":"J Hepatol"},{"issue":"10003","key":"904_CR8","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1016\/S0140-6736(15)00154-3","volume":"386","author":"EJ Carey","year":"2015","unstructured":"Carey EJ, Ali AH, Lindor KD. Primary biliary cirrhosis. Lancet. 2015;386(10003):1565\u201375.","journal-title":"Lancet"},{"issue":"6","key":"904_CR9","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1007\/s00535-002-1102-7","volume":"38","author":"T Kanda","year":"2003","unstructured":"Kanda T, et al. Bezafibrate treatment: a new medical approach for PBC patients? J Gastroenterol. 2003;38(6):573\u20138.","journal-title":"J Gastroenterol"},{"issue":"6","key":"904_CR10","doi-asserted-by":"publisher","first-page":"894","DOI":"10.3748\/wjg.v10.i6.894","volume":"10","author":"K Dohmen","year":"2004","unstructured":"Dohmen K, et al. Fenofibrate for patients with asymptomatic primary biliary cirrhosis. World J Gastroenterol. 2004;10(6):894\u20138.","journal-title":"World J Gastroenterol"},{"issue":"6","key":"904_CR11","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1111\/liv.14871","volume":"41","author":"AF Carrion","year":"2021","unstructured":"Carrion AF, Lindor KD, Levy C. Safety of fibrates in cholestatic liver diseases. Liver Int. 2021;41(6):1335\u201343.","journal-title":"Liver Int"},{"issue":"3","key":"904_CR12","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/j.jhep.2021.04.010","volume":"75","author":"A Tanaka","year":"2021","unstructured":"Tanaka A, et al. Association of bezafibrate with transplant-free survival in patients with primary biliary cholangitis. J Hepatol. 2021;75(3):565\u201371.","journal-title":"J Hepatol"},{"issue":"3","key":"904_CR13","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1053\/j.gastro.2020.12.019","volume":"160","author":"JK Dyson","year":"2021","unstructured":"Dyson JK, Jeffreys Jones DE. Bezafibrate for the treatment of cholestatic pruritus: time for a change in management? Gastroenterology. 2021;160(3):649\u201351.","journal-title":"Gastroenterology"},{"key":"904_CR14","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/1471-2288-14-135","volume":"14","author":"X Wan","year":"2014","unstructured":"Wan X, et al. Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range. BMC Med Res Methodol. 2014;14:135.","journal-title":"BMC Med Res Methodol"},{"issue":"6","key":"904_CR15","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1177\/0962280216669183","volume":"27","author":"D Luo","year":"2018","unstructured":"Luo D, et al. Optimally estimating the sample mean from the sample size, median, mid-range, and\/or mid-quartile range. Stat Methods Med Res. 2018;27(6):1785\u2013805.","journal-title":"Stat Methods Med Res"},{"issue":"4","key":"904_CR16","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.hepres.2004.04.001","volume":"29","author":"J Itakura","year":"2004","unstructured":"Itakura J, et al. Prospective randomized crossover trial of combination therapy with bezafibrate and UDCA for primary biliary cirrhosis. Hepatol Res. 2004;29(4):216\u201322.","journal-title":"Hepatol Res"},{"issue":"2","key":"904_CR17","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1007\/s00535-004-1518-3","volume":"40","author":"SM Akbar","year":"2005","unstructured":"Akbar SM, et al. Therapeutic efficacy of decreased nitrite production by bezafibrate in patients with primary biliary cirrhosis. J Gastroenterol. 2005;40(2):157\u201363.","journal-title":"J Gastroenterol"},{"issue":"7","key":"904_CR18","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1007\/s00535-006-1831-0","volume":"41","author":"R Kita","year":"2006","unstructured":"Kita R, et al. Bezafibrate may attenuate biliary damage associated with chronic liver diseases accompanied by high serum biliary enzyme levels. J Gastroenterol. 2006;41(7):686\u201392.","journal-title":"J Gastroenterol"},{"issue":"6","key":"904_CR19","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1111\/j.1872-034X.2007.00305.x","volume":"38","author":"S Iwasaki","year":"2008","unstructured":"Iwasaki S, et al. The efficacy of ursodeoxycholic acid and bezafibrate combination therapy for primary biliary cirrhosis: a prospective, multicenter study. Hepatol Res. 2008;38(6):557\u201364.","journal-title":"Hepatol Res"},{"key":"904_CR20","doi-asserted-by":"publisher","first-page":"120","DOI":"10.2174\/1874192401004010120","volume":"4","author":"EN Liberopoulos","year":"2010","unstructured":"Liberopoulos EN, et al. Fenofibrate in primary biliary cirrhosis: a pilot study. Open Cardiovasc Med J. 2010;4:120\u20136.","journal-title":"Open Cardiovasc Med J"},{"issue":"2","key":"904_CR21","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1111\/j.1365-2036.2010.04512.x","volume":"33","author":"C Levy","year":"2011","unstructured":"Levy C, et al. Pilot study: fenofibrate for patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid. Aliment Pharmacol Ther. 2011;33(2):235\u201342.","journal-title":"Aliment Pharmacol Ther"},{"issue":"9","key":"904_CR22","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1111\/j.1440-1746.2011.06737.x","volume":"26","author":"Y Takeuchi","year":"2011","unstructured":"Takeuchi Y, et al. Additive improvement induced by bezafibrate in patients with primary biliary cirrhosis showing refractory response to ursodeoxycholic acid. J Gastroenterol Hepatol. 2011;26(9):1395\u2013401.","journal-title":"J Gastroenterol Hepatol"},{"issue":"4","key":"904_CR23","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1111\/j.1751-2980.2012.00574.x","volume":"13","author":"XF Han","year":"2012","unstructured":"Han XF, et al. Efficacy of fenofibrate in Chinese patients with primary biliary cirrhosis partially responding to ursodeoxycholic acid therapy. J Dig Dis. 2012;13(4):219\u201324.","journal-title":"J Dig Dis"},{"issue":"5","key":"904_CR24","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1002\/hep.26018","volume":"57","author":"A Honda","year":"2013","unstructured":"Honda A, et al. Anticholestatic effects of bezafibrate in patients with primary biliary cirrhosis treated with ursodeoxycholic acid. Hepatology. 2013;57(5):1931\u201341.","journal-title":"Hepatology"},{"issue":"2","key":"904_CR25","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1111\/liv.12290","volume":"34","author":"S Lens","year":"2014","unstructured":"Lens S, et al. Bezafibrate normalizes alkaline phosphatase in primary biliary cirrhosis patients with incomplete response to ursodeoxycholic acid. Liver Int. 2014;34(2):197\u2013203.","journal-title":"Liver Int"},{"issue":"3","key":"904_CR26","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1038\/ajg.2015.20","volume":"110","author":"K Hosonuma","year":"2015","unstructured":"Hosonuma K, et al. A prospective randomized controlled study of long-term combination therapy using ursodeoxycholic acid and bezafibrate in patients with primary biliary cirrhosis and dyslipidemia. Am J Gastroenterol. 2015;110(3):423\u201331.","journal-title":"Am J Gastroenterol"},{"issue":"10","key":"904_CR27","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1002\/jhbp.281","volume":"22","author":"S Mizuno","year":"2015","unstructured":"Mizuno S, et al. Prospective study of bezafibrate for the treatment of primary sclerosing cholangitis. J Hepatobiliary Pancreat Sci. 2015;22(10):766\u201370.","journal-title":"J Hepatobiliary Pancreat Sci"},{"issue":"2","key":"904_CR28","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1111\/apt.13465","volume":"43","author":"AC Cheung","year":"2016","unstructured":"Cheung AC, et al. Combined ursodeoxycholic acid (UDCA) and fenofibrate in primary biliary cholangitis patients with incomplete UDCA response may improve outcomes. Aliment Pharmacol Ther. 2016;43(2):283\u201393.","journal-title":"Aliment Pharmacol Ther"},{"issue":"6","key":"904_CR29","doi-asserted-by":"publisher","first-page":"2035","DOI":"10.1002\/hep.30552","volume":"70","author":"A Honda","year":"2019","unstructured":"Honda A, et al. Bezafibrate improves GLOBE and UK-PBC scores and long-term outcomes in patients with primary biliary cholangitis. Hepatology. 2019;70(6):2035\u201346.","journal-title":"Hepatology"},{"issue":"3","key":"904_CR30","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1053\/j.gastro.2020.10.001","volume":"160","author":"E de Vries","year":"2021","unstructured":"de Vries E, et al. Fibrates for Itch (FITCH) in fibrosing cholangiopathies: a double-blind, randomized placebo-controlled trial. Gastroenterology. 2021;160(3):734-743.e6.","journal-title":"Gastroenterology"},{"key":"904_CR31","doi-asserted-by":"publisher","DOI":"10.23736\/S0026-4806.21.07316-X","author":"L Wang","year":"2021","unstructured":"Wang L, et al. Fenofibrate improves GLOBE and UK-PBC scores and histological features in primary biliary cholangitis. Minerva Med. 2021. https:\/\/doi.org\/10.23736\/S0026-4806.21.07316-X.","journal-title":"Minerva Med"},{"key":"904_CR32","doi-asserted-by":"publisher","first-page":"940688","DOI":"10.3389\/fimmu.2022.940688","volume":"13","author":"C Wang","year":"2022","unstructured":"Wang C, et al. Peroxisome proliferator-activated receptors regulate hepatic immunity and assist in the treatment of primary biliary cholangitis. Front Immunol. 2022;13:940688.","journal-title":"Front Immunol"},{"issue":"3","key":"904_CR33","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1002\/hep.1840140324","volume":"14","author":"MH Nathanson","year":"1991","unstructured":"Nathanson MH, Boyer JL. Mechanisms and regulation of bile secretion. Hepatology. 1991;14(3):551\u201366.","journal-title":"Hepatology"},{"key":"904_CR34","doi-asserted-by":"publisher","first-page":"847483","DOI":"10.3389\/fphar.2022.847483","volume":"13","author":"S Xu","year":"2022","unstructured":"Xu S, et al. Da-Chai-Hu-Tang Protects from acute intrahepatic cholestasis by inhibiting hepatic inflammation and bile accumulation via activation of PPAR\u03b1. Front Pharmacol. 2022;13:847483.","journal-title":"Front Pharmacol"},{"issue":"3","key":"904_CR35","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1053\/j.gastro.2005.12.029","volume":"130","author":"A Pares","year":"2006","unstructured":"Pares A, Caballeria L, Rodes J. Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic acid. Gastroenterology. 2006;130(3):715\u201320.","journal-title":"Gastroenterology"},{"issue":"12","key":"904_CR36","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1038\/s41569-021-00569-6","volume":"18","author":"D Montaigne","year":"2021","unstructured":"Montaigne D, Butruille L, Staels B. PPAR control of metabolism and cardiovascular functions. Nat Rev Cardiol. 2021;18(12):809\u201323.","journal-title":"Nat Rev Cardiol"},{"issue":"2","key":"904_CR37","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1038\/clpt.2011.124","volume":"90","author":"J Trottier","year":"2011","unstructured":"Trottier J, et al. Profile of serum bile acids in noncholestatic volunteers: gender-related differences in response to fenofibrate. Clin Pharmacol Ther. 2011;90(2):279\u201386.","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"904_CR38","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1007\/s00535-020-01681-z","volume":"55","author":"M Vesterhus","year":"2020","unstructured":"Vesterhus M, Karlsen TH. Emerging therapies in primary sclerosing cholangitis: pathophysiological basis and clinical opportunities. J Gastroenterol. 2020;55(6):588\u2013614.","journal-title":"J Gastroenterol"},{"issue":"3","key":"904_CR39","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1002\/hep.26894","volume":"59","author":"NS Ghonem","year":"2014","unstructured":"Ghonem NS, et al. Peroxisome proliferator-activated receptor \u03b1 activates human multidrug resistance transporter 3\/ATP-binding cassette protein subfamily B4 transcription and increases rat biliary phosphatidylcholine secretion. Hepatology. 2014;59(3):1030\u201342.","journal-title":"Hepatology"},{"issue":"5","key":"904_CR40","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1210\/er.2018-00064","volume":"39","author":"N Bougarne","year":"2018","unstructured":"Bougarne N, et al. Molecular actions of PPARalpha in lipid metabolism and inflammation. Endocr Rev. 2018;39(5):760\u2013802.","journal-title":"Endocr Rev"},{"issue":"2","key":"904_CR41","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1007\/s12072-021-10163-0","volume":"15","author":"N Kimura","year":"2021","unstructured":"Kimura N, et al. Paris II and Rotterdam criteria are the best predictors of outcomes in patients with primary biliary cholangitis in Japan. Hepatol Int. 2021;15(2):437\u201343.","journal-title":"Hepatol Int"},{"issue":"2","key":"904_CR42","first-page":"118","volume":"19","author":"WJ Duan","year":"2011","unstructured":"Duan WJ, et al. The clinical profiles of primary biliary cirrhosis with a suboptimal biochemical response to ursodeoxycholic acid. Zhonghua Gan Zang Bing Za Zhi. 2011;19(2):118\u201320.","journal-title":"Zhonghua Gan Zang Bing Za Zhi"},{"issue":"7","key":"904_CR43","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1016\/j.cgh.2018.12.007","volume":"17","author":"VS Hegade","year":"2019","unstructured":"Hegade VS, et al. Pruritus is common and undertreated in patients with primary biliary cholangitis in the United Kingdom. Clin Gastroenterol Hepatol. 2019;17(7):1379-1387 e3.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"904_CR44","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/ajg.2017.287","volume":"113","author":"A Reig","year":"2018","unstructured":"Reig A, Sese P, Pares A. Effects of bezafibrate on outcome and pruritus in primary biliary cholangitis with suboptimal ursodeoxycholic acid response. Am J Gastroenterol. 2018;113(1):49\u201355.","journal-title":"Am J Gastroenterol"},{"issue":"11","key":"904_CR45","doi-asserted-by":"publisher","first-page":"5020","DOI":"10.1093\/rheumatology\/keab231","volume":"60","author":"X Li","year":"2021","unstructured":"Li X, et al. Effects of fenofibrate therapy on renal function in primary gout patients. Rheumatology. 2021;60(11):5020\u20137 (Oxford).","journal-title":"Rheumatology"},{"issue":"6","key":"904_CR46","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1002\/hep4.1180","volume":"2","author":"M Carbone","year":"2018","unstructured":"Carbone M, et al. Clinical application of the GLOBE and United Kingdom-primary biliary cholangitis risk scores in a trial cohort of patients with primary biliary cholangitis. Hepatol Commun. 2018;2(6):683\u201392.","journal-title":"Hepatol Commun"},{"key":"904_CR47","doi-asserted-by":"publisher","first-page":"175628481878740","DOI":"10.1177\/1756284818787400","volume":"11","author":"P Santiago","year":"2018","unstructured":"Santiago P, Scheinberg AR, Levy C. Cholestatic liver diseases: new targets, new therapies. Therap Adv Gastroenterol. 2018;11:1756284818787400.","journal-title":"Therap Adv Gastroenterol"},{"issue":"10","key":"904_CR48","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1056\/NEJMc1809061","volume":"379","author":"DE Jones","year":"2018","unstructured":"Jones DE, Hegade VS. Bezafibrate in primary biliary cholangitis. N Engl J Med. 2018;379(10):984.","journal-title":"N Engl J Med"}],"container-title":["Clinical and Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-022-00904-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10238-022-00904-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-022-00904-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,29]],"date-time":"2023-11-29T22:02:15Z","timestamp":1701295335000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10238-022-00904-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,1]]},"references-count":48,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2023,9]]}},"alternative-id":["904"],"URL":"https:\/\/doi.org\/10.1007\/s10238-022-00904-2","relation":{},"ISSN":["1591-9528"],"issn-type":[{"value":"1591-9528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,1]]},"assertion":[{"value":"29 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 September 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}